Clinical Trial Update: Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE) [Phase 3]

View source ↗

Summary

A Phase 3 continuation study of budesonide oral suspension for eosinophilic esophagitis was terminated, and results were posted in December 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Drugs mentioned

• Budesonide oral suspension (budesonide)

Snippet

Sponsor: Shire | Conditions: Eosinophilic Esophagitis (EoE) | Phase 3 | Status: TERMINATED | Results posted: 2022-12-07